Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Crohn's disease phase 3 study of upadacitinib
2023-509618-12-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in Crohn's disease (4 arms), sponsored by AbbVie Inc. Primary endpoints: Clinical remission per PCDAI at Week 64, Endoscopic response at Week 64 and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-509618-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509618-12-00.